CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION
Idiopathic pulmonary arterial hypertension (IPAH) is a rather rare cardiovascular disease of unknown origin and, at the same time, the most common form of pulmonary arterial hypertension (PAH). It is characterized by increased mean pulmonary artery pressure of ≥ 25 mm Hg and increased pulmonary vasc...
Saved in:
| Main Authors: | Z. S. Valieva, T. V. Martynyuk |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
InterMedservice
2019-12-01
|
| Series: | Евразийский Кардиологический Журнал |
| Subjects: | |
| Online Access: | https://www.heartj.asia/jour/article/view/347 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
by: E. A. Rezukhina, et al.
Published: (2021-09-01) -
Patient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation
by: E. A. Rezukhina, et al.
Published: (2023-03-01) -
New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag
by: N. V. Ilyin, et al.
Published: (2019-12-01) -
Assessment of the effectiveness of PAH-specific therapy, including selexipag, in patients with idiopathic pulmonary hypertension according to a comprehensive examination using Raman spectroscopy
by: E. S. Allakhverdiev, et al.
Published: (2023-11-01) -
Possibility of evaluation of oxygen transport function in PAH patients on effective selexipag-based therapy
by: E. S. Allakhverdiev, et al.
Published: (2023-10-01)